![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Priller, EM Briley, J Mansouri, WA Devane, K Mackie and CC Felder
National Institute of Mental Health, Laboratory of Cell Biology, Bethesda, Maryland 20892, USA.
The recently discovered endogenous agonist for the cannabinoid receptor, anandamide (arachidonylethanolamide), can be formed enzymatically by the condensation of arachidonic acid with ethanolamine. 5Z,8Z,11Z-Eicosatrienoic acid (mead acid) has been found to substitute for arachidonic acid in the sn-2 position of phospholipids and accumulate during periods of dietary fatty acid deprivation in rats. In the present study, the chemically synthesized ethanolamide of mead acid was evaluated as a potential agonist at the two known subtypes of cannabinoid receptor: CB1 (central) and CB2 (peripheral). This compound was equipotent to anandamide in competing with [3H]CP55,940 binding to plasma membranes prepared from L cells expressing the human CB1 receptor and from ATt-20 cells expressing the human CB2 receptor. Mead ethanolamide was also equipotent to anandamide in inhibiting forskolin-stimulated cAMP accumulation in cells expressing the CB1 receptor. It inhibited N-type calcium currents with a lower potency than anandamide. Mead and arachidonic acid were equally efficacious as substrates for the enzymatic synthesis of their respective ethanolamides in rat and adult human hippocampal P2 membranes. Palmitic acid was not an effective substrate for the enzymatic synthesis of palmitoyl ethanolamide. Mead ethanolamide exhibits several characteristics of a novel agonist to CB1 and CB2 receptors and may represent another candidate endogenous ligand for the CB1 receptor. Due to the anticonvulsant properties of GABA and the positional similarity of L-serine to ethanolamine in membrane phospholipids, these compounds were synthetically coupled to arachidonic acid, and their resulting arachidonamides were tested as potential cannabinoid agonists. The arachidonamides of GABA and L- serine were inactive in both binding and functional assays at the CB1 receptor.
This article has been cited by other articles:
|
|
 |
|
  K. Soderstrom and F. Johnson Zebra Finch CB1 Cannabinoid Receptor: Pharmacology and in Vivo and in Vitro Effects of Activation J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 189 - 197. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. C.-K. Chan, T. R. Hinds, S. Impey, and D. R. Storm Hippocampal Neurotoxicity of Delta 9-Tetrahydrocannabinol J. Neurosci., July 15, 1998; 18(14): 5322 - 5332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Edgemond, C. J. Hillard, J. R. Falck, C. S. Kearn, and W. B. Campbell Human Platelets and Polymorphonuclear Leukocytes Synthesize Oxygenated Derivatives of Arachidonylethanolamide (Anandamide): Their Affinities for Cannabinoid Receptors and Pathways of Inactivation Mol. Pharmacol., July 1, 1998; 54(1): 180 - 188. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. L. Boger, J. E. Patterson, X. Guan, B. F. Cravatt, R. A. Lerner, and N. B. Gilula Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide PNAS, April 28, 1998; 95(9): 4810 - 4815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ouyang, S. G. Hwang, S. H. Han, and N. E. Kaminski Suppression of Interleukin-2 by the Putative Endogenous Cannabinoid 2-Arachidonyl-Glycerol Is Mediated through Down-regulation of the Nuclear Factor of Activated T Cells Mol. Pharmacol., April 1, 1998; 53(4): 676 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
A. Berger, G. Crozier, T. Bisogno, P. Cavaliere, S. Innis, and V. Di Marzo Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets PNAS, May 22, 2001; 98(11): 6402 - 6406. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
